uploads/2019/02/Graph-6-7-1.png

Here Are Zoetis’s Key Revenue Drivers in Fiscal 2019

By

Updated

Revenue performance in fiscal 2018

In fiscal 2018, Zoetis (ZTS) reported revenues of $5.83 billion, a YoY rise of 10.0% on a reported basis and 8% on an organic operational basis. The company reported revenues of $1.56 billion in the fourth quarter, a YoY rise of 7% on a reported basis. According to the company’s fourth-quarter earnings conference call, the company’s dermatology, parasiticides, vaccines, and the recently acquired Abaxis’ diagnostics products emerged as the key growth drivers for Zoetis in fiscal 2018.

Article continues below advertisement

Growth drivers

According to the company’s fourth-quarter earnings conference call, in fiscal 2018, Zoetis managed to report 12 products with annual sales greater than $100 million. Out of these, Simparica and Cytopoint made it to the blockbuster list with revenues of $158 million and $129 million, respectively, in fiscal 2018. Apoquel, the highest revenue earning asset for the company and indicated for allergic itch, managed to report sales of $464 million in fiscal 2018, a YoY rise of 28%.

According to the company’s fourth-quarter earnings conference call, in fiscal 2018, Zoetis has been focused on introducing next-generation products in its target markets. In fiscal 2018, the company introduced the swine vaccine, Fostera Gold PCV MH and topical parasiticide, Revolution Plus.

According to the company’s fourth-quarter earnings conference call, Zoetis expanded its manufacturing facility for poultry vaccines in Iowa in fiscal 2018 and is working on expanding its facility in Kalamazoo, Michigan. The company expects commercial supply from its Michigan facility to begin in mid-2019.

According to the company’s fourth-quarter earnings conference call, Zoetis plans to expand its vaccine manufacturing facility in China by the end of 2019. Further, the company has also acquired a facility in Ireland to expedite the production of bovine sealants for mastitis infection in cows.

Next, we’ll discuss risks for Elanco Animal Health and Zoetis in greater detail.

Advertisement

More From Market Realist